Leyden Labs is developing antibody-based nasal sprays that aim to stop viruses like flu and covid at the mucosa and with broad protection
Co-founder and CEO Koenraad Wiedhaup describes the shortcomings of today’s vaccines and why the company has chosen this unique approach. Plus, the history of virology expertise in Leiden and how Leyden Labs has attracted a slate of A-list life sciences investors.
.png){kind=logo}
